180 related articles for article (PubMed ID: 33192515)
1. Identification of Mutations Related to Cisplatin-Resistance and Prognosis of Patients With Lung Adenocarcinoma.
Li R; Liu J; Fang Z; Liang Z; Chen X
Front Pharmacol; 2020; 11():572627. PubMed ID: 33192515
[No Abstract] [Full Text] [Related]
2. Screening and Identifying Cisplatin-Related Gene Mutations in Lung Squamous Cell Carcinoma.
Li X; Wang Y; Hu S; Bai Y
Pharmgenomics Pers Med; 2020; 13():757-766. PubMed ID: 33376383
[TBL] [Abstract][Full Text] [Related]
3. Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors.
Niu Y; Lin A; Luo P; Zhu W; Wei T; Tang R; Guo L; Zhang J
Front Pharmacol; 2020; 11():1213. PubMed ID: 32903385
[TBL] [Abstract][Full Text] [Related]
4. Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors.
Wen Y; Lin A; Zhu W; Wei T; Luo P; Guo L; Zhang J
Front Pharmacol; 2021; 12():645862. PubMed ID: 34163353
[No Abstract] [Full Text] [Related]
5. Effect of TTN Mutations on Immune Microenvironment and Efficacy of Immunotherapy in Lung Adenocarcinoma Patients.
Wang Z; Wang C; Lin S; Yu X
Front Oncol; 2021; 11():725292. PubMed ID: 34513703
[TBL] [Abstract][Full Text] [Related]
6. Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.
Sun Y; Duan J; Fang W; Wang Z; Du X; Wang X; Li C; Cai S; Zhao J; Li S; Zhang L; Bai H; Wang J
BMC Med; 2021 Oct; 19(1):239. PubMed ID: 34615542
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma.
Lin X; Wang L; Xie X; Qin Y; Xie Z; Ouyang M; Zhou C
Front Mol Biosci; 2020; 7():602328. PubMed ID: 33330629
[TBL] [Abstract][Full Text] [Related]
8. Circular RNA CDR1-AS contributes to pemetrexed and cisplatin chemoresistance through EGFR/PI3K signaling pathway in lung adenocarcinoma.
Mao Y; Xu R
Biomed Pharmacother; 2020 Mar; 123():109771. PubMed ID: 31881486
[TBL] [Abstract][Full Text] [Related]
9.
Li M; Lin A; Luo P; Shen W; Xiao D; Gou L; Zhang J; Guo L
Aging (Albany NY); 2020 Jan; 12(2):1285-1303. PubMed ID: 31959735
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a DNA damage repair-related gene-based prediction model for the prognosis of lung adenocarcinoma.
Qin C; Fan X; Sai X; Yin B; Zhou S; Addeo A; Bian T; Yu H
J Thorac Dis; 2023 Dec; 15(12):6928-6945. PubMed ID: 38249902
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
Wu P; Zheng Y; Wang Y; Wang Y; Liang N
J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
[TBL] [Abstract][Full Text] [Related]
12. Nonnegative matrix factorization-based bioinformatics analysis reveals that TPX2 and SELENBP1 are two predictors of the inner sub-consensuses of lung adenocarcinoma.
Wang H; Wang X; Xu L; Cao H; Zhang J
Cancer Med; 2021 Dec; 10(24):9058-9077. PubMed ID: 34734491
[TBL] [Abstract][Full Text] [Related]
13. Increased Tumor Intrinsic Growth Potential and Decreased Immune Function Orchestrate the Progression of Lung Adenocarcinoma.
Zhao Y; Shang J; Gao J; Han H; Gao Z; Yan Y; Zheng Q; Ye T; Fu F; Deng C; Ma Z; Zhang Y; Zheng D; Zheng S; Li Y; Cao Z; Shi L; Chen H
Front Immunol; 2022; 13():921761. PubMed ID: 35844495
[TBL] [Abstract][Full Text] [Related]
14. Development of metastasis-associated seven gene signature for predicting lung adenocarcinoma prognosis using single-cell RNA sequencing data.
He J; Zhang W; Li F; Yu Y
Math Biosci Eng; 2021 Jul; 18(5):5959-5977. PubMed ID: 34517518
[TBL] [Abstract][Full Text] [Related]
15. A signature of tumor DNA repair genes associated with the prognosis of surgically-resected lung adenocarcinoma.
Yang X; Wang G; Gu R; Xu X; Zhu G
PeerJ; 2020; 8():e10418. PubMed ID: 33304656
[TBL] [Abstract][Full Text] [Related]
16. KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden.
Marinelli D; Mazzotta M; Scalera S; Terrenato I; Sperati F; D'Ambrosio L; Pallocca M; Corleone G; Krasniqi E; Pizzuti L; Barba M; Carpano S; Vici P; Filetti M; Giusti R; Vecchione A; Occhipinti M; Gelibter A; Botticelli A; De Nicola F; Ciuffreda L; Goeman F; Gallo E; Visca P; Pescarmona E; Fanciulli M; De Maria R; Marchetti P; Ciliberto G; Maugeri-Saccà M
Ann Oncol; 2020 Dec; 31(12):1746-1754. PubMed ID: 32866624
[TBL] [Abstract][Full Text] [Related]
17. Expression and prognostic analysis of Rho GTPase-activating protein 11A in lung adenocarcinoma.
Chen S; Duan H; Xie Y; Li X; Zhao Y
Ann Transl Med; 2021 May; 9(10):872. PubMed ID: 34164506
[TBL] [Abstract][Full Text] [Related]
18. TFAP2A Upregulates SKA3 to Promote Glycolysis and Reduce the Sensitivity of Lung Adenocarcinoma Cells to Cisplatin.
Liu G; Liu X; Zeng W; Zhou W
Pharmacology; 2024 Apr; ():1-14. PubMed ID: 38643755
[TBL] [Abstract][Full Text] [Related]
19. Elevated Heterogeneous Nuclear Ribonucleoprotein C Expression Correlates With Poor Prognosis in Patients With Surgically Resected Lung Adenocarcinoma.
Guo W; Huai Q; Zhang G; Guo L; Song P; Xue X; Tan F; Xue Q; Gao S; He J
Front Oncol; 2020; 10():598437. PubMed ID: 33569346
[TBL] [Abstract][Full Text] [Related]
20. The role of radiotherapy-related autophagy genes in the prognosis and immune infiltration in lung adenocarcinoma.
Gao J; Lu F; Yan J; Wang R; Xia Y; Wang L; Li L; Chang L; Li W
Front Immunol; 2022; 13():992626. PubMed ID: 36311724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
